FROM ALF 2020
Physicians are gaining a greater understanding of the pathophysiology of chronic graft-versus-host disease (cGVHD) in allo-hematopoietic cell transplantation (allo-HCT), a hematologist/oncologist told colleagues, and novel treatments are being tested.
However, options remain limited. There’s only one Food and Drug Administration–approved therapy for cGVHD that’s failed one or...